Sygnis foresees a near doubling of its net loss in 2009

Sygnis Pharma Ag said it expects its net loss to increase from €6.3 in the year ended March 2008 to €12 million in 2009 as it prepares for Phase 2b efficacy trials of AX200, its candidate for treating stroke.